相关临床试验
1
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1222
暂无试验阶段数据
招募中
1
100.0%
暂无批准数据
- A multicenter retrospective study of 401 patients found that liposomal amphotericin B achieved similar 90-day survival rates to triazoles in treating invasive aspergillosis. - The study revealed no statistically significant difference in mortality between the two treatment approaches, with 90-day survival rates of 58.8% for triazoles and 53.3% for liposomal amphotericin B. - Treatment modification was more common with liposomal amphotericin B, with 62.9% of patients switching therapy at a median of 10 days compared to 15.5% in the triazole group. - The findings suggest liposomal amphotericin B represents a viable alternative to standard triazole therapy, particularly for high-risk patients with drug resistance concerns.
- Researchers from Rutgers Health discovered that leukemia cells evade venetoclax treatment by producing high levels of OPA1 protein, which reshapes mitochondria to prevent cell death. - The team found that treatment-resistant leukemia cells develop tighter mitochondrial cristae that trap cytochrome c, blocking the apoptosis pathway normally triggered by venetoclax. - Experimental OPA1 inhibitors combined with venetoclax at least doubled survival time in mice with human leukemia cells compared to venetoclax alone. - The combination therapy worked across diverse leukemia subtypes, including cells with p53 mutations strongly associated with treatment resistance and poor outcomes.
- The DUAL-ACS trial found that 3 months of dual antiplatelet therapy (DAPT) showed signals for improved survival and lower bleeding risk compared to the standard 12-month duration in real-world heart attack patients. - The TARGET-FIRST trial demonstrated that P2Y12 inhibitor monotherapy after just one month of DAPT was noninferior to continued DAPT for cardiovascular outcomes while significantly reducing bleeding risk in low-risk patients. - Both studies challenge current ESC Guidelines recommending 12 months of DAPT after myocardial infarction, suggesting shorter treatment durations may be safer without compromising efficacy. - These findings could inform future guideline revisions for antiplatelet therapy management in post-MI patients, particularly those at low ischemic risk.
